补髓生血颗粒剂对慢性再生障碍性贫血相关造血调控机制的实验研究
|
摘要
目的:探讨补髓生血颗粒剂对慢性再生障碍性贫血(以下简称为CAA)患者的临床疗效及治疗前后骨髓造血干/祖细胞相关粘附分子L-选择素/CD62L、酪氨酸激酶受体FLT-3/CD135的表达水平和血清FL、IL-13水平。
方法:本研究将入选的68例CAA病人经半随机开放分为实验组和对照组,其中实验组35例,对照组33例。实验组给予补髓生血颗粒剂,对照组给予再障生血片,疗程为3个月,2个疗程后观察疗效,并对CAA患者治疗前后血象、骨髓象与CD62L、FLT-3、FL及IL-13的表达水平进行对比分析。
采用流式细胞技术检测CAA患者治疗前后骨髓CD62L及FLT-3的表达水平;采用酶联免疫(ELISA)法检测CAA患者治疗前后血清FL、IL-13水平的变化。
结果:
1.补髓生血颗粒剂治疗CAA的临床疗效优于再障生血片对照组(P<0.05),阳虚型疗效优于阴虚型(P<0.05)。
2.酪氨酸激酶受体FLT-3、CD62L在CAA发病中呈低表达状态,补髓生血颗粒能纠正CD62L的低表达,但对FLT-3的纠正作用不理想。
3. Flt-3配体FL、IL-13在CAA发病中呈高表达状态,补髓生血颗粒能有效降低二者的表达水平,且明显优于对照组再障生血片。
结论:补髓生血颗粒治疗CAA疗效优于再障生血片,进一步证实了本病有“阳虚易治,阴虚难调”的治疗规律。补髓生血颗粒可能通过提高酪氨酸激酶受体FLT-3、CD62L的表达水平来修复造血干/祖细胞的损伤,改善骨髓基质细胞的粘附功能,促进造血细胞的增殖、分化;同时补髓生血颗粒还可能通过降低FL、IL-13表达水平,调节T淋巴细胞分泌紊乱,抑制异常免疫功能介导的细胞毒性作用,减轻骨髓造血功能的损伤。补髓生血颗粒是防治
Objective: Discussed the clinical effect of chronic aplastic anemia (CAA) with Busuishengxue granule ,and observed the difference in expression levels of CD62L 、 FL、 FLT3、 IL-13 in CAA patients before and after treatment.Method: 68 CAA patients were randomly divided into experiment group and control group in which 35 patients in the experiment group while 33 in another. One curse of treatment was three months.We observed the clinical effect after two curses. Before and after treatment we observed and analyzed the change of hemogram、myelogram and the expression levels of CD62L、FLT3、 FL and IL-13.The experiment applied flow cytometer method (FCM) to examine the expression levels of bone marrow CD62L 、 FLT3, ELISA method to examine the change of FL and IL-13.RESULT: 1.The effect of Busuishengxue granule was superior to that of Zaizhangshengxue tablet (p<0.05). In experimental group, the curative effect of Yang deficiency type was superior to that of Yin deficiency type (P<0.05). 2. The expression levels of FLT3、 CD62L in CAA patients were low. Busuishengxue granule could improve the low expression level of CD62L ,but the effect to FLT3 was not satisfied.3. The expression levels of FL、 IL-13 in CAA patients were high. Busuishengxue granule could effectively reduce their expression levels and was superior to Zaizhangshengxue tablet evidently.Conclusion: The effect of Busuishengxue granule to CAA was superior to that of Zaizhangshengxue tablet. Our experiments further testified the theory "Yin deficiency is easy to treat, but Yang deficiency is difficult to treat". Busuishengxue granule could raise the expression levels of FLT3 、 CD62L to restore the damage of
hematopoietic stem cell,improve the adhesion function of BMSC, promote the multiplication and differentiation of hematopoietic cell. Busuishengxue granule could reduce the expression levels of FL% IL-13 to regulate T lymphocyte secretion disorder,restrain toxic cell effect led by abnormal immune function,relieve the damage of bone marrow hematopoietic function.Busuishengxue granule is an effective drug to treat CAA, and is worthy of further study and development.
方法:本研究将入选的68例CAA病人经半随机开放分为实验组和对照组,其中实验组35例,对照组33例。实验组给予补髓生血颗粒剂,对照组给予再障生血片,疗程为3个月,2个疗程后观察疗效,并对CAA患者治疗前后血象、骨髓象与CD62L、FLT-3、FL及IL-13的表达水平进行对比分析。
采用流式细胞技术检测CAA患者治疗前后骨髓CD62L及FLT-3的表达水平;采用酶联免疫(ELISA)法检测CAA患者治疗前后血清FL、IL-13水平的变化。
结果:
1.补髓生血颗粒剂治疗CAA的临床疗效优于再障生血片对照组(P<0.05),阳虚型疗效优于阴虚型(P<0.05)。
2.酪氨酸激酶受体FLT-3、CD62L在CAA发病中呈低表达状态,补髓生血颗粒能纠正CD62L的低表达,但对FLT-3的纠正作用不理想。
3. Flt-3配体FL、IL-13在CAA发病中呈高表达状态,补髓生血颗粒能有效降低二者的表达水平,且明显优于对照组再障生血片。
结论:补髓生血颗粒治疗CAA疗效优于再障生血片,进一步证实了本病有“阳虚易治,阴虚难调”的治疗规律。补髓生血颗粒可能通过提高酪氨酸激酶受体FLT-3、CD62L的表达水平来修复造血干/祖细胞的损伤,改善骨髓基质细胞的粘附功能,促进造血细胞的增殖、分化;同时补髓生血颗粒还可能通过降低FL、IL-13表达水平,调节T淋巴细胞分泌紊乱,抑制异常免疫功能介导的细胞毒性作用,减轻骨髓造血功能的损伤。补髓生血颗粒是防治
Objective: Discussed the clinical effect of chronic aplastic anemia (CAA) with Busuishengxue granule ,and observed the difference in expression levels of CD62L 、 FL、 FLT3、 IL-13 in CAA patients before and after treatment.Method: 68 CAA patients were randomly divided into experiment group and control group in which 35 patients in the experiment group while 33 in another. One curse of treatment was three months.We observed the clinical effect after two curses. Before and after treatment we observed and analyzed the change of hemogram、myelogram and the expression levels of CD62L、FLT3、 FL and IL-13.The experiment applied flow cytometer method (FCM) to examine the expression levels of bone marrow CD62L 、 FLT3, ELISA method to examine the change of FL and IL-13.RESULT: 1.The effect of Busuishengxue granule was superior to that of Zaizhangshengxue tablet (p<0.05). In experimental group, the curative effect of Yang deficiency type was superior to that of Yin deficiency type (P<0.05). 2. The expression levels of FLT3、 CD62L in CAA patients were low. Busuishengxue granule could improve the low expression level of CD62L ,but the effect to FLT3 was not satisfied.3. The expression levels of FL、 IL-13 in CAA patients were high. Busuishengxue granule could effectively reduce their expression levels and was superior to Zaizhangshengxue tablet evidently.Conclusion: The effect of Busuishengxue granule to CAA was superior to that of Zaizhangshengxue tablet. Our experiments further testified the theory "Yin deficiency is easy to treat, but Yang deficiency is difficult to treat". Busuishengxue granule could raise the expression levels of FLT3 、 CD62L to restore the damage of
hematopoietic stem cell,improve the adhesion function of BMSC, promote the multiplication and differentiation of hematopoietic cell. Busuishengxue granule could reduce the expression levels of FL% IL-13 to regulate T lymphocyte secretion disorder,restrain toxic cell effect led by abnormal immune function,relieve the damage of bone marrow hematopoietic function.Busuishengxue granule is an effective drug to treat CAA, and is worthy of further study and development.
引文
1.杨崇礼主编.再生障碍性贫血[M].第2版.天津:天津科技翻译出版公司,2000.1
2.梁冰.治疗再生障碍性贫血的思路[J].中医杂志,1995,36(12):749-750
3.彭粤训.柯微君治疗再生障碍性贫血经验[J].北京中医,1994,(4):6-7
4.寇孟珂.再生障碍性贫血“毒入骨髓”病机初探[J].四川中医,1996,14(10):8-9
5.黄振翘,黄韬,周永明,等.补肾泻肝方治疗再生障碍性贫血的临床研究[J].上海中医药大学学报,2000,14(1):20
6.麻柔,周霭详,郑金福.慢性再生障碍性贫血患者外周血T淋巴细胞亚群改变与中医分型的关系[J].中国中西医结合杂志,1992,12(3):142
7.孙伟正,曲佳丽,姚洪义,等.慢性再生障碍性贫血中医辨证治疗和免疫、骨髓造血细胞关系的研究[J].中医药信息,1994,11(3):39-43
8.罗秀素,虞荣喜,郑宝根,等.再生障碍性贫血辨证分型与体外骨髓造血祖细胞类型的关系[J].中国中西医结合杂志,1992,12(3):139
9.钟达锦.中西医结合治疗再生障碍性贫血46例临床分析[J].中西医结合杂志,1984,4(11):679-681
10.胡致平,沈一平,罗秀素,等.再生障碍性贫血患者甲状腺激素变化及其意义[J].1994,14(4):222-223
11.王运律,吴正翔,唐静芬,等.慢性再生障碍性贫血中医辨证与血浆皮质醇、T_3、T_4含量的关系初探[J].中国中西医结合杂志,1995,15(8):490
12.王介人.再障患者血清微量元素与中医辨证的关系[J].中医研究.1988,1(2):22
13.王继亮,杨淑莲,称广垠,等.再生障碍性贫血患者头发微量元素与辨证施治[J].中医杂志,1992,33(9):47
14.储榆林,杨天楹,梁骅.再生障碍性贫血中西医结合分型的探讨[J].中华血液学杂志,1985,6(8):478-481
15.俞亚琴.再生障碍性贫血中医辨证与甲皱微循环关系的研究[J].辽宁中医杂志,1996,(1):145
16.谢波,高丹,袁永强.不同中医证型再生障碍性贫血甲皱微循环异常及与外周血的关系[J].四川中医,1996,(1):15
17.孙伟正,杨东光,刚宏林.慢性再生障碍性贫血中医辨证分型与MHC-DRB1*等位基因的相关性研究[J].中医杂志,2004,45(6):450-452
18.赵新广,王祥麒,朱跃岚,等.补髓生血胶囊对慢性再生障碍性贫血患者造血干/祖细胞作用的实验研究[J].中医药信息,1998,15(3):53-55
19.曹克俭,俞亚琴,曹慧演,等.中药补髓生血Ⅰ、Ⅱ号冲剂对小鼠骨髓造血干(祖)细胞CFU-S、CFU-D、CFU-E的影响[J].天津中医学院学报,1996,(2):40-42
20.周霭详,王天恩,杨经敏,等.益肾生血片治疗再生障碍性贫血的实验研究[J].中国中西医结合杂志,1999,19(3):170-173
21.刘爱华,毕鸿雁,崔树岭,等.温肾阳与滋肾阴方治疗再生障碍性贫血实验研究[J].山东中医杂志,1998,17(4):176-177
22.梁毅,鲁新华,陈如泉.中药复方对免疫介导小鼠再生障碍性贫血红系造血祖细胞的影响[J].中国中医基础医学杂志,1999,5(6):13-15
23.谢鸣,王绵之,谢仁敷.中医补血法的实验研究-填精补血方和活血生血方对小 鼠骨髓造血的影响[J].北京中医学院学报,1992,15(4):23-26
24.虞荣喜,罗秀素,高瑞兰,等.69例再生障碍性贫血分型和中西医结合治疗的研究[J].中国中西医结合杂志,1994,14(1):14-17
25.后盾,吴正翔.白术对再生障碍性贫血骨髓红系造血祖细胞促增殖作用的实验研究[J].江西中医学院学报,1999,11(1):28
26.周永明,黄振翘,薛志忠,等.健脾补肾活血方对再生障碍性贫血有关免疫学指标的影响[J].上海中医药杂志,1998,(12):12-14
27.黄韬,黄振翘,周永明,等.补肾泻肝方对再生障碍性贫血造血与免疫失调治疗的实验研究[J].中国中西医结合杂志,1998,(18)(增刊):189
28.黄韬,黄振翘,周永明.补肾泻肝方对再生障碍性贫血的疗效与血清sIL-2R关系的研究[J].上海中医药杂志,1999,(5):47-48
29.周永明,黄韬,薛志忠,等.生血合剂对免疫介导再生障碍性贫血小鼠作用的实验研究[J].中医药研究,1998,14(5):43-46
30.史亦谦,汤金土,陈瑜.中药对免疫介导性再生障碍性贫血T淋巴细胞的实验研究[J].中国中医急症,1998,7(3):128-130
31.郑瑾,刘强,王宗仁,等.化瘀补肾汤对再生障碍性贫血小鼠CFU-F及血清IL-2、IFNγ的影响[J].安徽中医学院学报,2004,23(4):33-35
32.孙伟正,罗梅宏,李海霞,等.补髓生血冲剂对慢性再生障碍性贫血患者血清可溶性Fas、肿瘤坏死因子、白细胞介素2表达作用的影响[J].中医杂志,2001,42 (9): 546-547
33.孙伟正,王祥琪,袁斌华,等.应用“补髓生血冲剂”治疗24例慢性再生障碍性贫血骨髓CD34、CD10变化规律的分析[J].中医药信息,1994,11(2):28-30
34.舒砚君,孙汉英,董凌莉,等.川芎嗪对免疫介导再生障碍性贫血小鼠骨髓细胞CD34抗原表达的影响[J].中国中西医结合杂志,1998,18(2):107-108
35.孙汉英,董凌莉,刘文励,等.复方活血汤对再生障碍性贫血小鼠骨髓造血细胞粘附分子及细胞周期蛋白表达作用[J].中国中西医结合杂志,1999,19(2):100-102
36.董凌莉,刘文励,孙汉英,等.川芎嗪对再生障碍性贫血小鼠骨髓细胞粘附分子作用研究[J].中华血液学杂志,1999,20(4):178-179
37.陈志雄,曹克俭,薛恺睿,等.火髓片对环磷酰胺造模小鼠骨髓细胞DNA含量及细胞周期的影响[J].中医杂志,1999,40(11):686-687
38.王运津,吴正祥.补肾活血方对慢性骨髓障碍小鼠的实验研究[J],天津中医,1995,12(6):32-33
39.朱跃岚,孙伟正.补髓生血胶囊治疗慢性再生障碍性贫血临床研究[J].北京中医药大学学报,1998,21(5):48-49
40.谢鸣,黄启福,王绵之.中医补血法的实验研究—填精补血方和活血生血方对环磷酰胺损伤小鼠骨髓作用的电镜观察[J].北京中医学院学报,1991,14(4):36-38
41.刘文励,黄伟,和美冬,等.复方活血汤对辐射损伤小鼠骨髓基质细胞粘附功能的影响[J].中国中西医结合杂志,1997,17(6):354-355
42.舒砚君,孙汉英,刘文励,等.复方活血汤对免疫介导诱导再生障碍性贫血小鼠骨髓造血微环境作用的研究[J].中国中西医结合杂志,199818(6):359-361
43.全国再生障碍性贫血协作组.再生障碍性贫血危险因素的病例对照研究[J].中华血液学杂志,2003,24(11):599-601
44.王俊和,高莉.氨苄青霉素过敏致急性再生障碍性贫血一例[J].中华内科杂志, 1995,34(6):387
45.李晶.外用氯霉素眼药水后发生再生障碍性贫血一例[J].中华内科杂志,1994,33(11):769
46.王智宏,洪镇杰,魏久勋,等.超剂量硫唑嘌呤致一过性再生障碍性贫血一例[J].中华内科杂志,1994,33(9):580
47.曾淑荣,娄陵生,黎学先,等.苯中毒致再生障碍性贫血32例[J].中华血液学杂志,1997,18(4):208
48.杨云芳,郭君兵,苏美云,等.苯中毒引起重型再生障碍性贫血四例[J].中华内科杂志,2003,42(8):597
49.林果为,林佩娣,杨子文,等.病毒性肝炎和再生障碍性贫血发病关系的临床流行病学研究[J].中华血液学杂志,1994,15(4):171-173
50. Maciejewski JP, Anderson S, Katevas P, et al. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure[J]. Br J Haematol, 1994, 87:227—234
51.石淑文,宋华,汤永民,等.34例小儿再生障碍性贫血骨髓CD34~+细胞的检测[J].中华血液学杂志,2002,23(5):267—268
52. Asano H, Hotta T, Ichihara M;et al. Growth analysis of marrow CD34positive hematopoietic progenitor cells in patients with myelodysplastic syndrome[J]s. Leukemia, 1994, 8:833—838
53. Sato T, Kim S, Selleri C, et al. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome [J]. Leukemia, 1998, 12: 1187—1194
54. Marsh JCM, et al. In vitro ssessment of marrow stem celt and stromal cell function in aplastic anemia [J]. Br J Haematol, 1991, 78: 258
55. Amano Y, Koike K, Nakahata T. Stem cell factor enhances the growth ofprimitive erythroid progenitors to a greater extent than interleukin-3 in patients with aplastic anemia [J]. Br J Haematol, 1993, 85: 663—669
56. Gibson FM, Scopes J, Daly S, et al. In vitro response of normal and aplastic anemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interlerkin-3 [J].Exp Hematol, 1994, 22:302—312
57. Wodnar-Filipowicz A, Chklovskaia E, Manz CY, et al. Effect of Flt3 lig and on in vitro growth and expansion of colonyforming bone marrow cells from patients with aplastic anemia[J]. Exp Hematol, 1997, 25: 573—581
58.袁宇宁,杨勤,陈永振,等.再生障碍性贫血患者血清sFas受体检测及其临床意义[J].中国实用内科杂志,2004,24(9):533—534
59. Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anemia [J].Br J Haematol, 1997, 98 (1): 18—20
60. Young NS. Autoimmunity and its treatment in aplastic anemia [J]. Ann Internrn Med, 1997, 126 : 166—168
61. Nakao S. Immune mechanism of aplastic anemia [J]. Int J Hematol, 1997, 66: 127—134
62.宋振岚,谢普耀,范成明,等.再生障碍性贫血免疫发病机制的探讨[J].中华血液学杂志,1996,17(4):173—175
63. Melenhorst JJ, Krieken J H, Dreef E, et al. Tcells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anemia[J]. Br J Haematol, 1997, 99: 517
64.胡国柱,陈璋,文珠,等.再生障碍性贫血T淋巴细胞亚群及其功能研究[J].中华血液学杂志,1999,20(10):538—539
65. Hsu HC, Tsai WH, Chen LY, et.al. Overproduction of inhibitory hematopoietic cytokines by lipopolysaccharide-activated peripheral blood mononuclear cells in patients with aplastic anemia[J]. Ann Hematol, 1995, 71:281—286
66.夏长青,储榆林,张君奎,等.严重型再生障碍性贫血患者骨髓和外周血HLA-DR~+T细胞的变化及其淋巴细胞造血抑制活性的研究[J].中华血液学杂志,1997,18(4):186—189
67.王冠军.再生障碍性贫血病人骨髓及外周血T淋巴细胞亚群与造血抑制的关系[J].中华内科杂志,1990,13(4):229—230
68. Nagasawa T, Hasegawa Y, Shimizu S. et al. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects[J], Br J Hematol, 1998, 101:242
69.曾风华,沈柏均,时庆,等.再生障碍性贫血患者骨髓T淋巴细胞的研究[J].中华血液学杂志,1997,18(11):542—543
70. Manz CY, Dietrich PY, Schnuriger V, et al. T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia[J]. Blood Cells Mol Dis, 1997, 23: 110—122
71. Nakao S, Takamatsu H, Yachie A, et al. Establishment of a CD4~+ T cell clone recognizing autologous hematpopietic progenitor cells from a patient with immune-mediated aplastic anemia[J]. Exp Hematol, 1995, 23:433—438
72. Koijima S. Hematopoietic growth factors and marrow stroma in aplastic anemia[J]. Intern J Hematol, 1998, 68: 19—28
73. Fujiwara M. Granulocyte colony-stimulating factor and granutocyte [J]. Acta Haematol Jpn, 1990, 75:421
74. Gibson FM, et al. Erythropoietin and platelet production [J]. Br J Haematol, 1995 , 91(8): 551—561
75. Nissen C, Wodnar-Filipowiez A, Slanicka-Krieger M, et al. Eur J Haematol, 1995, 55 (6): 255—261
76. Holmberg L, Seidel K, Leisenring W, et al. Cyclosporin A in aplastic anemia report a workshop[J]. Blood, 1994, 84 (11): 3685—3690
77.刘杰文,齐淑玲.长期培养的人骨髓基质细胞中有关造血调节的粘附蛋白表达的研究[J].中华血液学杂志,1997,18(8):468—469
78.陈文杰,朱平.血液分子生物学[M].第一版.北京:中国医药科技出版社,1993.49—51
79.董爱英,王润田,马立人.20例再生障碍性贫血的细胞因子和粘附分子的表达分析[J].中华检验医学杂志,2002,25(3):156—158
80.邵宗鸿,陈桂彬,张泓,等.再生障碍性贫血患者骨髓造血干/祖细胞c-kit受体表达[J].中华血液学杂志,1999,20(10):532—534
81.王军,孟晓晖,冯剑飞,等.再生障碍性贫血患儿血浆可溶性干细胞因子及其 受体水平的测定[J].中华血液学杂志,2003,24(11):603—604
82. Kojima S, Matsuyama T, Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anemia[J]. Br J Hematol, 1997, 99:440-446
83.董孝媛,徐从高,孙国瑞,等.阵发性睡眠性血红蛋白尿、再生障碍性贫血和骨髓增生异常综合征患者三种GPI-锚蛋白的表达及临床意义[J].中华血液学杂志,2004,25(4):198—201
84. Tsuge I, Kojima S, Matsulka H, et al. Blood cell cytoadhesion molecules [J]. Br.J Hematol, 1993, 84(1): 137-143
85.杨碧云,汤爱萍,石庆之,等.再生障碍性贫血患者HLA-DR B_1 *1501检测[J].中华血液学杂志,2002,23(5):276
86. Frickhofen N, Rosenfeld S. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine [J]. Semin Hematol, 2000, 37:56-68
87.战榕,陈志哲,梁玉英,等.抗淋巴细胞球蛋白联合雄激素治疗重型再生障碍性贫血的临床研究[J].中华内科杂志,1999,38(11):781—782
88.任翠爱,张茂宏,徐从高,等.环孢菌素A治疗对再生障碍性贫血患者骨髓细胞凋亡的影响[J].中华血液学杂志,2001,22(4):189—192
89.贾志凌,巩伟丽,梅巍,等.环孢菌素A对再生障碍性贫血和骨髓增生异常综合征造血祖细胞的作用[J].中华内科杂志,2001,40(1):47—48
90. Nabel GJ. A transformed view of cyclosporine [J]. Nature, 1999, 397:471—472
91. Tisdale JF, Dunn DE, Maciejewski J. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia[J]. Semin Hematol, 2000,37:102-109
92. Brodsky RA, Sensenbrenner LL, Jone RJ, et al. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation[J]. Blood, 1996,87:491-494
93.鄢毅,丁凡.大剂量甲基泼尼松龙治疗急性再生障碍性贫血10例疗效观察[J].中华内科杂志,1997,36(1):49—50
94.何广胜,邵宗鸿.再生障碍性贫血的免疫抑制治疗现状[J].中华血液学杂志,2002,23(11):611—613
95. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, and granulocyte-colony stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients[J]. Blood, 2000,95:1931-1934
96.杨崇礼.再生障碍性贫血.见:张之南,沈悌,主编.血液病诊断及疗效标准[M].第2版.北京:科学出版社,1998.33—38.
97. Tedder TF, Penti AC, Levine HB, et al. Expression of the human leukocyte adhension molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens [J]. J Immunol, 1990,144(2):532-5402.
98. Bevilacqua MP, Nelson RM.J Clin Invest 1993;91:379
99. Kansas GS. APMIS 1992;100:287 4. Jutila MA. APMIS 1992;100:191
100. Aizawa S. Tavassoli M. Molecular basis of the recognition of intravenously transplanted hemopoietic ceus by bone marrow. Proe Natl Aead Sci USA, 1988, 85: 3180
101.Lesley J,Hyman R, Kincade PW. Adv. Immunol, 1993;54:271~335
102. Sackstein R, Dimitroff CJ. A hematopoietic cell L-selectin ligand that is distinct from PSGL-land displays N-glycan-dependent binding activity [J].Blood. 2000, 96 (8): 2765~2774
103.Majdic O,Stockl J, Pickl WF,et al. Signaling and indction of enhanneed cytoadhesiveness via the hematopoietic progenitor cell surface molecule CD34 . Blood, 1994, 83: 1226~1234
104. Watanabe T, et al. Biochim Biophys . Acta 1992;1131: 321
105. Varki A.Selectin Ligands[J].PNAS. 1994,91 (16):7390~7393
106. Malhotor R,Taylor NR.Bird MI.Anionic phospholipids bind to L-selectin(but not E-selectin at asite distinct the distinct from the carbohyrate-binding site[J].Biochem J. 1996,314 (1) : 297~303
107.Gallatin WM, et al. Nature 1983;304:30
108.Williams TJ, Hellewell PG. .Am Rev Respir Dis 1992;146:545
109.Mackay CR, lmhof BA. Immunol Today 1993:14:99
110.Springer TA, Nature 1990:346:425
111.Gallatin WM, et al. Nature 1983;304:30
112.Lawrence MB et al. Cell, 1991:65:859
113.Mwangi W, Brown WC, Lewin HA, et al. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colonystimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNIA vaccination of outbred animals. J Immunol, 2002. 169 (7) : 3837-3846
114. Hung CF, Hsu KF, Cheng WF. Enhancement of DNA vaccme potency by linkage of antigen gene to a gene encoding the extracellular domain of Fins-like tyrosine kinase 3-ligand. Cancer Rcs , 2001,61(3) : 1080-1088.
115. Beslu N, Larose J, Casteran N, et al. Phosphatidylmostol-3' kinase is not required for mitogenesis or internalization of the Flt3/ Flk2 receptor tyrosine kinase. J Biol Chem, 1996, 271(33): 20075-20087.
116. Zhang S, Mantel C, Broxmeyer HE. FLT3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/FIt3 cells. J Leukoc Biol, 1999, 65(3): 372-380.
117.Griffithin J, Black J, Faerman C, et al. The structural basis for autoinhbition of FLT-3 by the juxt'amembrane domain .Mol Cell, 2004,13:169~178.
118.Chklovskais E, Jansen W, Nissen C, et al. Mechanism of flt3 ligand expression in bone marrow failure: translocation fromintracellular stores to the surface to T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood,1999,93: 2595~2640.
119. Mosley RL, Parajuli P, Pisarev V, et al. Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/ memory T cells. Int Immunopharmacol, 2002, 2: 925~940.
120. Stroble H, Bello- Fernandez C, Riedl E, et al. Flt3 ligand in
cooperation with transforming growth factor-beta 1 potentiateds in vitro development of Langerhans-type dendritic cells and allows single-cells dendritic cell cluster formation under serum-free condition. Blood, 1997,90: 1425～1434.
121. Shaw SG, Maung AA, Steptoe RJ, et al. Expansion of functional NK cells in multiple tissue compartments of mice treated with flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol, 1998,161:2817～2824.
122. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: multiple dendritic cell subpopulations identified .J Exp Med, 1996,184: 1953～1962
123. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15 .Blood, 1998, 92: 3647～3657.
124. Jacobsen SE, okkenhaug c, Veiby OP, et al. In-terleukin 13: Novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells[J] .J Exp Med, 1994,180(1): 75—82.
125. Xi X, Schlegel N, Caen JP, et al. Differential ef-fects of recombinant human interleukine—13 on the in vitro growth of human haemopoietic progenitor cells [J]. Br J Haematol, 1995, 90(4):921—927.
126.韩忠朝,陆敏,奚晓东,等.细胞介素13刺激体外巨核细胞生成作用研究[J].中华血液学杂志,1996,17(3):128—131.
127.石晓玉,李文林,奚晓东,等.Effect of Internleukin-13 on growth of human erythroleukemia cell line[J].中国病理生理杂志,1997,13(4):337-340.
128.李文林,石小玉,熊丽霞,等.Dami cell proliferation stimulated by recombinant human Internleukin-13 [J].中国病理生理杂志,1999:15(12):1113-1115.
129. Lopez M, Amorim L, Gane P, et al. IL-13 induces CD34 cell sisolated fron G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells [J]. Immunol Methods, 1997, 208 (2):117—129.
130. Rosenzwajg M, Cames S, Guigon M, et al. Theinfluence of interleukin (IL)-4, IL-13, and Flt3ligand on human dendritic cell differentiation form cord blood CD34 progenitor cells [J]. Exp Hematol, 1998, 26(1): 63-72.
131. Di Nicola M, Longoni P, Magni M, et al. The influence of interleukine (IL)-4 and IL-13 on human dendritic cell differentiation form CD34 progenitor cells: the importance of the source of serum [J].Exp Hematol, 1999,27(2): 386-387.
132. Lai YH, Heslan JM, Poppema S, et al. Continuous administration of IL-13 to mice induces extramedullary hemopoiesis and monocytosis[J]. J Immunol, 1996,156(9): 3166-3173.
133. Renard N, Duvert V, Banchereau J, et al. Intrleukine-13 in hibits the proliferation of normal and leukemic terleukine-13 in human B-cell precursors [J]. Blood, 1994, 84(7): 2253—2260.
134.Sakamoto O, Hashiyama M, Minty A, et al. Interleukin-13 selectively suppresses the growth of humanma crophage progenitors at the late stage[J].Blood, 1995, 85(12): 3487-3493.
2.梁冰.治疗再生障碍性贫血的思路[J].中医杂志,1995,36(12):749-750
3.彭粤训.柯微君治疗再生障碍性贫血经验[J].北京中医,1994,(4):6-7
4.寇孟珂.再生障碍性贫血“毒入骨髓”病机初探[J].四川中医,1996,14(10):8-9
5.黄振翘,黄韬,周永明,等.补肾泻肝方治疗再生障碍性贫血的临床研究[J].上海中医药大学学报,2000,14(1):20
6.麻柔,周霭详,郑金福.慢性再生障碍性贫血患者外周血T淋巴细胞亚群改变与中医分型的关系[J].中国中西医结合杂志,1992,12(3):142
7.孙伟正,曲佳丽,姚洪义,等.慢性再生障碍性贫血中医辨证治疗和免疫、骨髓造血细胞关系的研究[J].中医药信息,1994,11(3):39-43
8.罗秀素,虞荣喜,郑宝根,等.再生障碍性贫血辨证分型与体外骨髓造血祖细胞类型的关系[J].中国中西医结合杂志,1992,12(3):139
9.钟达锦.中西医结合治疗再生障碍性贫血46例临床分析[J].中西医结合杂志,1984,4(11):679-681
10.胡致平,沈一平,罗秀素,等.再生障碍性贫血患者甲状腺激素变化及其意义[J].1994,14(4):222-223
11.王运律,吴正翔,唐静芬,等.慢性再生障碍性贫血中医辨证与血浆皮质醇、T_3、T_4含量的关系初探[J].中国中西医结合杂志,1995,15(8):490
12.王介人.再障患者血清微量元素与中医辨证的关系[J].中医研究.1988,1(2):22
13.王继亮,杨淑莲,称广垠,等.再生障碍性贫血患者头发微量元素与辨证施治[J].中医杂志,1992,33(9):47
14.储榆林,杨天楹,梁骅.再生障碍性贫血中西医结合分型的探讨[J].中华血液学杂志,1985,6(8):478-481
15.俞亚琴.再生障碍性贫血中医辨证与甲皱微循环关系的研究[J].辽宁中医杂志,1996,(1):145
16.谢波,高丹,袁永强.不同中医证型再生障碍性贫血甲皱微循环异常及与外周血的关系[J].四川中医,1996,(1):15
17.孙伟正,杨东光,刚宏林.慢性再生障碍性贫血中医辨证分型与MHC-DRB1*等位基因的相关性研究[J].中医杂志,2004,45(6):450-452
18.赵新广,王祥麒,朱跃岚,等.补髓生血胶囊对慢性再生障碍性贫血患者造血干/祖细胞作用的实验研究[J].中医药信息,1998,15(3):53-55
19.曹克俭,俞亚琴,曹慧演,等.中药补髓生血Ⅰ、Ⅱ号冲剂对小鼠骨髓造血干(祖)细胞CFU-S、CFU-D、CFU-E的影响[J].天津中医学院学报,1996,(2):40-42
20.周霭详,王天恩,杨经敏,等.益肾生血片治疗再生障碍性贫血的实验研究[J].中国中西医结合杂志,1999,19(3):170-173
21.刘爱华,毕鸿雁,崔树岭,等.温肾阳与滋肾阴方治疗再生障碍性贫血实验研究[J].山东中医杂志,1998,17(4):176-177
22.梁毅,鲁新华,陈如泉.中药复方对免疫介导小鼠再生障碍性贫血红系造血祖细胞的影响[J].中国中医基础医学杂志,1999,5(6):13-15
23.谢鸣,王绵之,谢仁敷.中医补血法的实验研究-填精补血方和活血生血方对小 鼠骨髓造血的影响[J].北京中医学院学报,1992,15(4):23-26
24.虞荣喜,罗秀素,高瑞兰,等.69例再生障碍性贫血分型和中西医结合治疗的研究[J].中国中西医结合杂志,1994,14(1):14-17
25.后盾,吴正翔.白术对再生障碍性贫血骨髓红系造血祖细胞促增殖作用的实验研究[J].江西中医学院学报,1999,11(1):28
26.周永明,黄振翘,薛志忠,等.健脾补肾活血方对再生障碍性贫血有关免疫学指标的影响[J].上海中医药杂志,1998,(12):12-14
27.黄韬,黄振翘,周永明,等.补肾泻肝方对再生障碍性贫血造血与免疫失调治疗的实验研究[J].中国中西医结合杂志,1998,(18)(增刊):189
28.黄韬,黄振翘,周永明.补肾泻肝方对再生障碍性贫血的疗效与血清sIL-2R关系的研究[J].上海中医药杂志,1999,(5):47-48
29.周永明,黄韬,薛志忠,等.生血合剂对免疫介导再生障碍性贫血小鼠作用的实验研究[J].中医药研究,1998,14(5):43-46
30.史亦谦,汤金土,陈瑜.中药对免疫介导性再生障碍性贫血T淋巴细胞的实验研究[J].中国中医急症,1998,7(3):128-130
31.郑瑾,刘强,王宗仁,等.化瘀补肾汤对再生障碍性贫血小鼠CFU-F及血清IL-2、IFNγ的影响[J].安徽中医学院学报,2004,23(4):33-35
32.孙伟正,罗梅宏,李海霞,等.补髓生血冲剂对慢性再生障碍性贫血患者血清可溶性Fas、肿瘤坏死因子、白细胞介素2表达作用的影响[J].中医杂志,2001,42 (9): 546-547
33.孙伟正,王祥琪,袁斌华,等.应用“补髓生血冲剂”治疗24例慢性再生障碍性贫血骨髓CD34、CD10变化规律的分析[J].中医药信息,1994,11(2):28-30
34.舒砚君,孙汉英,董凌莉,等.川芎嗪对免疫介导再生障碍性贫血小鼠骨髓细胞CD34抗原表达的影响[J].中国中西医结合杂志,1998,18(2):107-108
35.孙汉英,董凌莉,刘文励,等.复方活血汤对再生障碍性贫血小鼠骨髓造血细胞粘附分子及细胞周期蛋白表达作用[J].中国中西医结合杂志,1999,19(2):100-102
36.董凌莉,刘文励,孙汉英,等.川芎嗪对再生障碍性贫血小鼠骨髓细胞粘附分子作用研究[J].中华血液学杂志,1999,20(4):178-179
37.陈志雄,曹克俭,薛恺睿,等.火髓片对环磷酰胺造模小鼠骨髓细胞DNA含量及细胞周期的影响[J].中医杂志,1999,40(11):686-687
38.王运津,吴正祥.补肾活血方对慢性骨髓障碍小鼠的实验研究[J],天津中医,1995,12(6):32-33
39.朱跃岚,孙伟正.补髓生血胶囊治疗慢性再生障碍性贫血临床研究[J].北京中医药大学学报,1998,21(5):48-49
40.谢鸣,黄启福,王绵之.中医补血法的实验研究—填精补血方和活血生血方对环磷酰胺损伤小鼠骨髓作用的电镜观察[J].北京中医学院学报,1991,14(4):36-38
41.刘文励,黄伟,和美冬,等.复方活血汤对辐射损伤小鼠骨髓基质细胞粘附功能的影响[J].中国中西医结合杂志,1997,17(6):354-355
42.舒砚君,孙汉英,刘文励,等.复方活血汤对免疫介导诱导再生障碍性贫血小鼠骨髓造血微环境作用的研究[J].中国中西医结合杂志,199818(6):359-361
43.全国再生障碍性贫血协作组.再生障碍性贫血危险因素的病例对照研究[J].中华血液学杂志,2003,24(11):599-601
44.王俊和,高莉.氨苄青霉素过敏致急性再生障碍性贫血一例[J].中华内科杂志, 1995,34(6):387
45.李晶.外用氯霉素眼药水后发生再生障碍性贫血一例[J].中华内科杂志,1994,33(11):769
46.王智宏,洪镇杰,魏久勋,等.超剂量硫唑嘌呤致一过性再生障碍性贫血一例[J].中华内科杂志,1994,33(9):580
47.曾淑荣,娄陵生,黎学先,等.苯中毒致再生障碍性贫血32例[J].中华血液学杂志,1997,18(4):208
48.杨云芳,郭君兵,苏美云,等.苯中毒引起重型再生障碍性贫血四例[J].中华内科杂志,2003,42(8):597
49.林果为,林佩娣,杨子文,等.病毒性肝炎和再生障碍性贫血发病关系的临床流行病学研究[J].中华血液学杂志,1994,15(4):171-173
50. Maciejewski JP, Anderson S, Katevas P, et al. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure[J]. Br J Haematol, 1994, 87:227—234
51.石淑文,宋华,汤永民,等.34例小儿再生障碍性贫血骨髓CD34~+细胞的检测[J].中华血液学杂志,2002,23(5):267—268
52. Asano H, Hotta T, Ichihara M;et al. Growth analysis of marrow CD34positive hematopoietic progenitor cells in patients with myelodysplastic syndrome[J]s. Leukemia, 1994, 8:833—838
53. Sato T, Kim S, Selleri C, et al. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome [J]. Leukemia, 1998, 12: 1187—1194
54. Marsh JCM, et al. In vitro ssessment of marrow stem celt and stromal cell function in aplastic anemia [J]. Br J Haematol, 1991, 78: 258
55. Amano Y, Koike K, Nakahata T. Stem cell factor enhances the growth ofprimitive erythroid progenitors to a greater extent than interleukin-3 in patients with aplastic anemia [J]. Br J Haematol, 1993, 85: 663—669
56. Gibson FM, Scopes J, Daly S, et al. In vitro response of normal and aplastic anemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interlerkin-3 [J].Exp Hematol, 1994, 22:302—312
57. Wodnar-Filipowicz A, Chklovskaia E, Manz CY, et al. Effect of Flt3 lig and on in vitro growth and expansion of colonyforming bone marrow cells from patients with aplastic anemia[J]. Exp Hematol, 1997, 25: 573—581
58.袁宇宁,杨勤,陈永振,等.再生障碍性贫血患者血清sFas受体检测及其临床意义[J].中国实用内科杂志,2004,24(9):533—534
59. Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anemia [J].Br J Haematol, 1997, 98 (1): 18—20
60. Young NS. Autoimmunity and its treatment in aplastic anemia [J]. Ann Internrn Med, 1997, 126 : 166—168
61. Nakao S. Immune mechanism of aplastic anemia [J]. Int J Hematol, 1997, 66: 127—134
62.宋振岚,谢普耀,范成明,等.再生障碍性贫血免疫发病机制的探讨[J].中华血液学杂志,1996,17(4):173—175
63. Melenhorst JJ, Krieken J H, Dreef E, et al. Tcells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anemia[J]. Br J Haematol, 1997, 99: 517
64.胡国柱,陈璋,文珠,等.再生障碍性贫血T淋巴细胞亚群及其功能研究[J].中华血液学杂志,1999,20(10):538—539
65. Hsu HC, Tsai WH, Chen LY, et.al. Overproduction of inhibitory hematopoietic cytokines by lipopolysaccharide-activated peripheral blood mononuclear cells in patients with aplastic anemia[J]. Ann Hematol, 1995, 71:281—286
66.夏长青,储榆林,张君奎,等.严重型再生障碍性贫血患者骨髓和外周血HLA-DR~+T细胞的变化及其淋巴细胞造血抑制活性的研究[J].中华血液学杂志,1997,18(4):186—189
67.王冠军.再生障碍性贫血病人骨髓及外周血T淋巴细胞亚群与造血抑制的关系[J].中华内科杂志,1990,13(4):229—230
68. Nagasawa T, Hasegawa Y, Shimizu S. et al. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects[J], Br J Hematol, 1998, 101:242
69.曾风华,沈柏均,时庆,等.再生障碍性贫血患者骨髓T淋巴细胞的研究[J].中华血液学杂志,1997,18(11):542—543
70. Manz CY, Dietrich PY, Schnuriger V, et al. T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia[J]. Blood Cells Mol Dis, 1997, 23: 110—122
71. Nakao S, Takamatsu H, Yachie A, et al. Establishment of a CD4~+ T cell clone recognizing autologous hematpopietic progenitor cells from a patient with immune-mediated aplastic anemia[J]. Exp Hematol, 1995, 23:433—438
72. Koijima S. Hematopoietic growth factors and marrow stroma in aplastic anemia[J]. Intern J Hematol, 1998, 68: 19—28
73. Fujiwara M. Granulocyte colony-stimulating factor and granutocyte [J]. Acta Haematol Jpn, 1990, 75:421
74. Gibson FM, et al. Erythropoietin and platelet production [J]. Br J Haematol, 1995 , 91(8): 551—561
75. Nissen C, Wodnar-Filipowiez A, Slanicka-Krieger M, et al. Eur J Haematol, 1995, 55 (6): 255—261
76. Holmberg L, Seidel K, Leisenring W, et al. Cyclosporin A in aplastic anemia report a workshop[J]. Blood, 1994, 84 (11): 3685—3690
77.刘杰文,齐淑玲.长期培养的人骨髓基质细胞中有关造血调节的粘附蛋白表达的研究[J].中华血液学杂志,1997,18(8):468—469
78.陈文杰,朱平.血液分子生物学[M].第一版.北京:中国医药科技出版社,1993.49—51
79.董爱英,王润田,马立人.20例再生障碍性贫血的细胞因子和粘附分子的表达分析[J].中华检验医学杂志,2002,25(3):156—158
80.邵宗鸿,陈桂彬,张泓,等.再生障碍性贫血患者骨髓造血干/祖细胞c-kit受体表达[J].中华血液学杂志,1999,20(10):532—534
81.王军,孟晓晖,冯剑飞,等.再生障碍性贫血患儿血浆可溶性干细胞因子及其 受体水平的测定[J].中华血液学杂志,2003,24(11):603—604
82. Kojima S, Matsuyama T, Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anemia[J]. Br J Hematol, 1997, 99:440-446
83.董孝媛,徐从高,孙国瑞,等.阵发性睡眠性血红蛋白尿、再生障碍性贫血和骨髓增生异常综合征患者三种GPI-锚蛋白的表达及临床意义[J].中华血液学杂志,2004,25(4):198—201
84. Tsuge I, Kojima S, Matsulka H, et al. Blood cell cytoadhesion molecules [J]. Br.J Hematol, 1993, 84(1): 137-143
85.杨碧云,汤爱萍,石庆之,等.再生障碍性贫血患者HLA-DR B_1 *1501检测[J].中华血液学杂志,2002,23(5):276
86. Frickhofen N, Rosenfeld S. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine [J]. Semin Hematol, 2000, 37:56-68
87.战榕,陈志哲,梁玉英,等.抗淋巴细胞球蛋白联合雄激素治疗重型再生障碍性贫血的临床研究[J].中华内科杂志,1999,38(11):781—782
88.任翠爱,张茂宏,徐从高,等.环孢菌素A治疗对再生障碍性贫血患者骨髓细胞凋亡的影响[J].中华血液学杂志,2001,22(4):189—192
89.贾志凌,巩伟丽,梅巍,等.环孢菌素A对再生障碍性贫血和骨髓增生异常综合征造血祖细胞的作用[J].中华内科杂志,2001,40(1):47—48
90. Nabel GJ. A transformed view of cyclosporine [J]. Nature, 1999, 397:471—472
91. Tisdale JF, Dunn DE, Maciejewski J. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia[J]. Semin Hematol, 2000,37:102-109
92. Brodsky RA, Sensenbrenner LL, Jone RJ, et al. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation[J]. Blood, 1996,87:491-494
93.鄢毅,丁凡.大剂量甲基泼尼松龙治疗急性再生障碍性贫血10例疗效观察[J].中华内科杂志,1997,36(1):49—50
94.何广胜,邵宗鸿.再生障碍性贫血的免疫抑制治疗现状[J].中华血液学杂志,2002,23(11):611—613
95. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, and granulocyte-colony stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients[J]. Blood, 2000,95:1931-1934
96.杨崇礼.再生障碍性贫血.见:张之南,沈悌,主编.血液病诊断及疗效标准[M].第2版.北京:科学出版社,1998.33—38.
97. Tedder TF, Penti AC, Levine HB, et al. Expression of the human leukocyte adhension molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens [J]. J Immunol, 1990,144(2):532-5402.
98. Bevilacqua MP, Nelson RM.J Clin Invest 1993;91:379
99. Kansas GS. APMIS 1992;100:287 4. Jutila MA. APMIS 1992;100:191
100. Aizawa S. Tavassoli M. Molecular basis of the recognition of intravenously transplanted hemopoietic ceus by bone marrow. Proe Natl Aead Sci USA, 1988, 85: 3180
101.Lesley J,Hyman R, Kincade PW. Adv. Immunol, 1993;54:271~335
102. Sackstein R, Dimitroff CJ. A hematopoietic cell L-selectin ligand that is distinct from PSGL-land displays N-glycan-dependent binding activity [J].Blood. 2000, 96 (8): 2765~2774
103.Majdic O,Stockl J, Pickl WF,et al. Signaling and indction of enhanneed cytoadhesiveness via the hematopoietic progenitor cell surface molecule CD34 . Blood, 1994, 83: 1226~1234
104. Watanabe T, et al. Biochim Biophys . Acta 1992;1131: 321
105. Varki A.Selectin Ligands[J].PNAS. 1994,91 (16):7390~7393
106. Malhotor R,Taylor NR.Bird MI.Anionic phospholipids bind to L-selectin(but not E-selectin at asite distinct the distinct from the carbohyrate-binding site[J].Biochem J. 1996,314 (1) : 297~303
107.Gallatin WM, et al. Nature 1983;304:30
108.Williams TJ, Hellewell PG. .Am Rev Respir Dis 1992;146:545
109.Mackay CR, lmhof BA. Immunol Today 1993:14:99
110.Springer TA, Nature 1990:346:425
111.Gallatin WM, et al. Nature 1983;304:30
112.Lawrence MB et al. Cell, 1991:65:859
113.Mwangi W, Brown WC, Lewin HA, et al. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colonystimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNIA vaccination of outbred animals. J Immunol, 2002. 169 (7) : 3837-3846
114. Hung CF, Hsu KF, Cheng WF. Enhancement of DNA vaccme potency by linkage of antigen gene to a gene encoding the extracellular domain of Fins-like tyrosine kinase 3-ligand. Cancer Rcs , 2001,61(3) : 1080-1088.
115. Beslu N, Larose J, Casteran N, et al. Phosphatidylmostol-3' kinase is not required for mitogenesis or internalization of the Flt3/ Flk2 receptor tyrosine kinase. J Biol Chem, 1996, 271(33): 20075-20087.
116. Zhang S, Mantel C, Broxmeyer HE. FLT3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/FIt3 cells. J Leukoc Biol, 1999, 65(3): 372-380.
117.Griffithin J, Black J, Faerman C, et al. The structural basis for autoinhbition of FLT-3 by the juxt'amembrane domain .Mol Cell, 2004,13:169~178.
118.Chklovskais E, Jansen W, Nissen C, et al. Mechanism of flt3 ligand expression in bone marrow failure: translocation fromintracellular stores to the surface to T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood,1999,93: 2595~2640.
119. Mosley RL, Parajuli P, Pisarev V, et al. Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/ memory T cells. Int Immunopharmacol, 2002, 2: 925~940.
120. Stroble H, Bello- Fernandez C, Riedl E, et al. Flt3 ligand in
cooperation with transforming growth factor-beta 1 potentiateds in vitro development of Langerhans-type dendritic cells and allows single-cells dendritic cell cluster formation under serum-free condition. Blood, 1997,90: 1425～1434.
121. Shaw SG, Maung AA, Steptoe RJ, et al. Expansion of functional NK cells in multiple tissue compartments of mice treated with flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol, 1998,161:2817～2824.
122. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: multiple dendritic cell subpopulations identified .J Exp Med, 1996,184: 1953～1962
123. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15 .Blood, 1998, 92: 3647～3657.
124. Jacobsen SE, okkenhaug c, Veiby OP, et al. In-terleukin 13: Novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells[J] .J Exp Med, 1994,180(1): 75—82.
125. Xi X, Schlegel N, Caen JP, et al. Differential ef-fects of recombinant human interleukine—13 on the in vitro growth of human haemopoietic progenitor cells [J]. Br J Haematol, 1995, 90(4):921—927.
126.韩忠朝,陆敏,奚晓东,等.细胞介素13刺激体外巨核细胞生成作用研究[J].中华血液学杂志,1996,17(3):128—131.
127.石晓玉,李文林,奚晓东,等.Effect of Internleukin-13 on growth of human erythroleukemia cell line[J].中国病理生理杂志,1997,13(4):337-340.
128.李文林,石小玉,熊丽霞,等.Dami cell proliferation stimulated by recombinant human Internleukin-13 [J].中国病理生理杂志,1999:15(12):1113-1115.
129. Lopez M, Amorim L, Gane P, et al. IL-13 induces CD34 cell sisolated fron G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells [J]. Immunol Methods, 1997, 208 (2):117—129.
130. Rosenzwajg M, Cames S, Guigon M, et al. Theinfluence of interleukin (IL)-4, IL-13, and Flt3ligand on human dendritic cell differentiation form cord blood CD34 progenitor cells [J]. Exp Hematol, 1998, 26(1): 63-72.
131. Di Nicola M, Longoni P, Magni M, et al. The influence of interleukine (IL)-4 and IL-13 on human dendritic cell differentiation form CD34 progenitor cells: the importance of the source of serum [J].Exp Hematol, 1999,27(2): 386-387.
132. Lai YH, Heslan JM, Poppema S, et al. Continuous administration of IL-13 to mice induces extramedullary hemopoiesis and monocytosis[J]. J Immunol, 1996,156(9): 3166-3173.
133. Renard N, Duvert V, Banchereau J, et al. Intrleukine-13 in hibits the proliferation of normal and leukemic terleukine-13 in human B-cell precursors [J]. Blood, 1994, 84(7): 2253—2260.
134.Sakamoto O, Hashiyama M, Minty A, et al. Interleukin-13 selectively suppresses the growth of humanma crophage progenitors at the late stage[J].Blood, 1995, 85(12): 3487-3493.